4 articles
Eli Lilly sued six companies for illegally selling unapproved black-market versions of its experimental obesity drug retatrutide, currently in Phase 3 trials. Highlighting safety risks, the firm urged
Eli Lilly announced an expanded access program for its experimental obesity drug retatrutide prior to FDA approval for specific severe cases. The company plans to file for approval in Q1 next year fol
Eli Lilly shares rose 4% following compelling Phase III data for obesity drug retatrutide, showing 19% weight loss at a lower dose. Analysts view this as strengthening Lilly's leadership against rival
S&P 500 and Nasdaq futures rose as chip stocks rebounded, while crude oil prices surged over 4% amid Middle East tensions. Eli Lilly shares gained following positive clinical trial results for its obe
ChemBrief